Pulmonary Arterial Hypertension Market Size By Drug Class (Prostacyclin And Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators, Endothelin Receptor Antagonist (ERA), Phosphodiesterase 5 (PDE-5), Vasodilators), By Route of Administration (Oral, Intravenous, Inhalation), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Published Date: Aug 2021  |  Report ID: GMI1939  |  Authors: Sumant Ugalmugale, Rupali Swain

Report Format: PDF   |   Pages: 120   |   Base Year: 2020




Summary Table of Contents Industry Coverage Methodology

Industry Trends

Pulmonary Arterial Hypertension (PAH) Market size exceeded USD 6.6 billion in 2020 and is anticipated to grow at a CAGR of 6% between 2021 and 2027. The strong product pipeline and novel drug combination awaiting approval are expected to boost the market growth. Furthermore, pulmonary arterial hypertension is a rare lung disorder that is commonly reported in children. The high proportion of children suffering from untreated PAH offers immense market expansion opportunities and is poised to promote the use of pulmonary arterial hypertension drugs.
 

Pulmonary Arterial Hypertension Market Overview

Get more details on this report - Request Free Sample PDF
 

However, side effects associated with the drugs may negatively influence the market progression. Vasodilators are widely prescribed for the treatment of patients with PAH to open blocked and narrowed blood vessels. Studies report that vasodilators have a number of side effects such as tachycardia, edema, heart palpitations, chest pain, etc. Owing to the substantial side effects associated with the use of vasodilators in chronically ill patients, the U.S. FDA regulates the use of this drug. Further, the PAH drugs that treat high blood pressure and dilate blood vessels require to submit reasonable assurance regarding the safety and effectiveness of the drugs. These drugs require the U.S. FDA approval before commercializing in the market. The FDA drug approval represents a complicated process that demonstrates the safety and efficacy of the drug. Hence, a time-consuming regulatory process and side effects related to the use of PAH drugs might hamper the industry growth during the forecast timeframe.
 

The pulmonary arterial hypertension market has been slightly impacted credited to the COVID-19 and the slender effects of the coronavirus pandemic may remain in the coming years. The impact of coronavirus outbreak on the industry peaked during early 2020 wherein, pulmonary arterial hypertension patients were at a higher risk of suffering from coronavirus. Other challenges including hindrance in diagnostic testing, changed guidelines pertaining to the hospital & emergency care, and interrupted drug supply chain among others had impeded the industry expansion. The pandemic has exhibited the importance of PAH drugs as a response to the increasing number of hospitalized PAH-COVID-19 patients.
 

Rising geriatric population globally will stimulate the industry progression

Rising geriatric population base in developing countries is positively influencing the market value. According to the United Nations report, in 2020, the aging population accounted for around 727 million people aged 65 years or above worldwide. This number is projected to grow in the coming decades by two-fold, reaching over 1.5 billion by 2050. As per the United Nations Population Fund and HelpAge India statistics, the number of elderly adults in India will reach to 173 million by 2026. Thus, with the significant proportion of population aging, the frequency of PAH in the elderly population will increase in the foreseeable future. Rising age is one of the non-modifiable factors that surges the risk related to PAH. Additionally, the elderly population base is prone to this disease due to diastolic dysfunction and age-associated blood vessel stiffening that further augments the business demand.
 

Several educational and awareness programs are initiated by market players and the government to increase the awareness level for PAH in healthcare providers and patients. These programs further prove beneficial for the elderly population base as it raises the awareness level amongst them. Several government organizations such as the WHO, Million Hearts, and others have undertaken certain initiatives to create awareness that accelerates the business revenue.
 

Growing demand for endothelin receptor antagonist is set to promote the pulmonary arterial hypertension market expansion

The endothelin receptor antagonist segment is predicted to witness 5.5% growth rate through 2027 owing to the rising demand for endothelin receptor antagonist drugs. These drugs are widely recommended as a targeted therapy to reverse the damage of the heart & lungs, slow the progression of PAH, and dilate blood vessels among others. The clinical studies have confirmed that patient with pulmonary arterial hypertension produces high amount of endothelin that often leads to high blood pressure. Thus, an endothelin receptor antagonist is highly prescribed by physicians to reduce the amount of endothelin present in the blood vessels. Moreover, progressive investments for research and development of endothelin receptor antagonist will promote the segment growth. Recently there has been a rapid expansion in research targeting endothelin receptor that has other therapeutic advantages, mainly in the treatment of pulmonary arterial hypertension.
 

Numerous advantages offered by oral drug administration is poised to impel the market growth

Pulmonary Arterial Hypertension Market Size

Get more details on this report - Request Free Sample PDF
 

The oral segment in the pulmonary arterial hypertension market dominated more than 69% of the revenue share in 2020 led by the oral route of administration that offers a broad range of dosage forms such as tablets, capsules, and solutions among others. The oral route is the most preferred route for drug administration attributed to its benefits including the convenience of drug administration, patient compliance, and non-invasiveness. Oral therapies increase patient safety and comfort at an affordable cost. Furthermore, rapid delivery of drugs, a higher rate of bioavailability, and high efficacy among others will propel the segment revenue.
 

Increase in prevalence of pulmonary arterial hypertension in the North America region is slated to foster the regional growth

Global Pulmonary Arterial Hypertension Market

Get more details on this report - Request Free Sample PDF
 

U.S. dominated the North America pulmonary arterial hypertension market and will reach USD 6.25 billion by 2027 driven by the numerous factors such as the availability of a high number of board-certified physicians, growing hospital admissions related to PAH, and growing supportive government initiatives among others. The prevalence of PAH is increasing in the country attributed to the risk factors comprising smoking, HIV, sedentary lifestyle, and alcohol consumption among others. In addition, in the U.S., the Orphan Drug Act (ODA) was introduced in 1983 to provide incentives for industry investment in treatments for PAH.
 

In Europe, Germany market held 10% of revenue share in 2020 and is predicted to cross USD 194 million by 2027 on account of the increase in the prevalence of pulmonary arterial hypertension, optimal health workforce, and facilitative government initiatives to improve the health of patients suffering from PAH in the country. As per the article published by the National Center for Biotechnology Information, in 2016, left heart disease is one of the common factors causing PAH that affected around 1.3 million people in Germany. According to the article published in 2020, over 5.6 million health workers were working in Germany. A large health workforce highlights well-developed healthcare infrastructure in the country. The German health care system covers over 80% of the medical costs of its residents is assisting the patients to avail the quality of treatment for pulmonary arterial hypertension.
 

Strategies adopted by prominent players are projected to spur the industry demand

Some of the major companies operating in the market are Bayer AG, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, and Johnson & Johnson among others. These major participants are adopting strategic formulations such as new product development & commercialization, commercial expansion, distribution agreements for business expansion. Moreover, these leaders are investing heavily in developing products, thereby fuelling the revenue generation.
 

Recent industry developments:

  • In June 2021, United Therapeutics Corporation received the U.S. FDA approval for Tyvaso DPI. Tyvaso DPI ((inhalation treprostinil) is used for the treatment of pulmonary arterial hypertension and interstitial lung disease. This approval will strengthen the company’s market position and further assist in the revenue growth. 
     
  • In June 2017, Johnson & Johnson announced the acquisition of Actelion, a biopharmaceutical company engaged in the development of pulmonary arterial hypertension drugs. This acquisition offered competitive advantages to the company, further propelling the product sales.
     

Pulmonary arterial hypertension market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Drug Class, 2016 - 2027 (USD Million)

  • Prostacyclin And Prostacyclin Analogs
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Endothelin Receptor Antagonist (ERA)
  • Phosphodiesterase 5 (PDE-5)
  • Vasodilators
  • Others

Market, By Route of Administration, 2016 - 2027 (USD Million)

  • Oral
  • Intravenous
  • Inhalation

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea 
  • Latin America
    • Brazil
    • Mexico
    • Argentina 
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

 

Frequently Asked Questions (FAQ) :

Pulmonary arterial hypertension market size had surpassed USD 6.6 billion in 2020 and will witness a CAGR of 6% through 2027.
Endothelin receptor antagonist segment will observe a CAGR of 5.5% through 2027 as the drug is highly recommended to reverse the damage of heart & lungs and slow the progression of PAH.
Oral segment had captured a revenue share of over 69% in 2020 owing to higher preference for this route of administration due to the convenience and non-invasiveness.
U.S. dominated North America pulmonary arterial hypertension market and will record a valuation of over USD 6.25 billion by 2027 owing to increasing hospital admissions for PAH and growing supportive government initiatives.
Germany held 10% of the market share in 2020 and will record over USD 194 million by 2027 owing to rising prevalence of PAH in the country.

Premium Report Details

  • Published Date: Aug 2021
  • Pages: 120
  • Tables: 130
  • Charts / Figures: 13
  • Companies covered: 7
  • Countries covered: 18

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X